NCT01872988View on ClinicalTrials.gov

Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Chronic Hepatitis BHepatocellular Carcinoma
Interventions
DRUG

Tenofovir

Administer Tenofovir to HCC patients who are indicated for TACE after randomization

DRUG

Placebo

Administer Placebo to HCC patients who are indicated for TACE after randomization

Trial Locations (4)

104

Mackay Memorial Hosp, Taipei

407

Taichung Veterans General Hospital, Taichung

539

Chia-Yi Christine Hospital, Chiayi City

824

E-Da Hospital, Kaohsiung City

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

Taipei Institute of Pathology

OTHER_GOV

lead

Taichung Veterans General Hospital

OTHER